Nootropic and Neuropeptide Compounds

Nootropic peptides are short-chain amino acid sequences that influence cognitive function, neuroprotection, or neuropsychiatric symptoms through mechanisms distinct from conventional pharmaceutical drugs. Unlike small-molecule nootropics (racetams, modafinil) or nutritional supplements, peptide-based nootropics typically act through neurotrophin signalling, receptor modulation, or gene expression changes that alter the brain’s own repair and adaptation systems rather than directly agonising or blocking neurotransmitter receptors.

The most extensively studied nootropic peptides emerged from a single programme at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Under the direction of Professor N.F. Myasoedov, this laboratory produced both of the two best-characterised compounds in the category – Semax and Selank – using an identical design strategy: take a biologically active parent peptide, append a Pro-Gly-Pro stabilisation tail to extend its half-life, and deliver the result intranasally for direct CNS access. The two compounds work through entirely different mechanisms because they are built on different parent molecules, but they share an origin, a delivery method, and a design philosophy.

Beyond the Russian programme, several other neuropeptides have attracted research interest for cognitive applications, including DSIP (delta sleep-inducing peptide), Cerebrolysin (a porcine brain-derived peptide mixture), VIP (vasoactive intestinal peptide), and Dihexa. These compounds differ significantly in their evidence bases, mechanisms, and regulatory trajectories.

The bottom line: nootropic peptides represent a pharmacological approach to cognition that works through the brain’s own growth factor, receptor, and gene expression systems rather than through direct neurotransmitter manipulation – promising in principle but with evidence concentrated in a small number of research groups.

Semax (ACTH-Derived Cognitive Stimulant)

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment that retains ACTH’s neurotrophic effects without its hormonal cortisol-stimulating activity. Its primary mechanism is upregulation of BDNF and its receptor trkB in the hippocampus, combined with dopaminergic and serotonergic modulation. Semax has been approved in Russia since the 1990s for ischemic stroke, cognitive decline, and optic nerve disorders, with a 110-patient stroke rehabilitation study representing the largest published clinical data. The FDA removed Semax from Category 2 on April 15, 2026 and scheduled it for PCAC review on July 24, 2026 for cerebral ischaemia, migraine, and trigeminal neuralgia.

Selank (Tuftsin-Derived Anxiolytic)

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the immune peptide tuftsin, using the same Pro-Gly-Pro stabilisation strategy as Semax but producing fundamentally different effects. Its primary mechanism is GABA-A receptor modulation at a non-benzodiazepine site, combined with enkephalinase inhibition and serotonin modulation – producing anxiolytic effects comparable to benzodiazepines in Russian clinical trials without sedation, cognitive impairment, or dependence. Approved in Russia since 2009 for generalised anxiety disorder, Selank was removed from FDA Category 2 in September 2024 but has no scheduled PCAC review date.

DSIP / Emideltide (Sleep Regulation)

DSIP (delta sleep-inducing peptide), also known by its INN Emideltide, is a nonapeptide originally isolated from rabbit brain in 1977 by Swiss researchers Schoenenberger and Monnier. It modulates sleep architecture, stress response, and pain perception through mechanisms that remain incompletely characterised. DSIP is scheduled for PCAC review on July 23, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy – making it one of only seven peptides on the July agenda.

Cerebrolysin (Brain-Derived Peptide Mixture)

Cerebrolysin is a proprietary mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue, manufactured by EVER Pharma (Austria). Unlike the single-entity peptides in this cluster, Cerebrolysin’s composition is not fully characterised – it contains neurotrophic fragments that mimic BDNF, NGF, and CNTF activity. It has more Western clinical trial data than most compounds in this category, including controlled studies in stroke, traumatic brain injury, and Alzheimer’s disease, and is approved in multiple countries (though not by the FDA).

Additional Compounds

Several other peptides with cognitive or neuropeptide relevance will be covered in upcoming guides: VIP (vasoactive intestinal peptide), which has gained niche interest in the CIRS (chronic inflammatory response syndrome) community; Dihexa, a hexapeptide analog of angiotensin IV with preclinical evidence for hepatocyte growth factor receptor activation and cognitive enhancement at picomolar concentrations; and Kisspeptin-10, primarily studied for reproductive neuroendocrine function. A head-to-head comparison of the two flagship compounds is covered in Semax vs Selank (forthcoming).

Compound	Primary Target	Key Mechanism	Best Human Evidence	Regulatory Status (US)
Semax	Cognition, neuroprotection	BDNF/trkB upregulation, dopamine/serotonin modulation	110-patient stroke study (non-randomised)	PCAC July 24, 2026
Selank	Anxiety, immune modulation	GABA-A modulation, enkephalinase inhibition	250+ patients across multiple benzo-comparison trials	Cat 2 removed Sept 2024, PCAC referred, no date
DSIP / Emideltide	Sleep, opioid withdrawal	Sleep architecture modulation, stress response	Small European and Russian studies	PCAC July 23, 2026
Cerebrolysin	Neuroprotection, neuroregeneration	Multi-neurotrophin mimicry (BDNF/NGF/CNTF fragments)	Multiple controlled trials in stroke and TBI	Not FDA-approved, no 503A pathway
VIP	Neuroendocrine, CIRS	VIP receptor agonism, anti-inflammatory	Limited; primarily Shoemaker CIRS protocols	Not scheduled for PCAC
Dihexa	Cognition (preclinical only)	HGF receptor activation at picomolar doses	None (animal data only)	PCAC before Feb 2027

The bottom line: Selank has the strongest human clinical evidence in this cluster (multiple active-controlled trials), Semax has the deepest preclinical characterisation (genome-wide transcriptome studies), and Cerebrolysin has the broadest international clinical footprint – but none has been evaluated by a Western regulatory agency to the standard required for drug approval.

Understanding the nootropic peptide landscape requires understanding its origin: the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, under the direction of N.F. Myasoedov. This single laboratory produced Semax and Selank using an identical design strategy (biologically active parent peptide + Pro-Gly-Pro stabilisation tail + intranasal delivery) applied to two different starting molecules (ACTH fragment for Semax, tuftsin for Selank). The result was two compounds with complementary, non-overlapping mechanisms that are frequently combined in Russian clinical practice.

Both compounds are registered pharmaceuticals in Russia – Semax for stroke and cognitive decline, Selank for generalised anxiety disorder. Both have been prescribed for decades in Russian hospitals. Both have published clinical data in Russian-language journals with Western-indexed preclinical studies. And both face the same limitation: virtually all evidence originates from institutions with direct ties to the development programme, and no independent Western replication of the key clinical findings exists.

This concentration is not evidence of fraud – the studies are internally consistent, published in indexed journals, and supported by detailed molecular data. But it means the entire evidence base for both compounds depends on the credibility of a single research ecosystem. Independent replication remains the missing step.

The bottom line: the Semax-Selank programme represents perhaps the most ambitious peptide neuroscience effort in history, but the evidence base is one laboratory deep – extensive within that laboratory, absent outside it.

The July 23-24, 2026 PCAC hearing at the FDA’s White Oak Campus in Silver Spring, Maryland, will review several neuropeptide compounds for potential inclusion on the Section 503A Bulk Drug Substances List. On Day 2 (July 24), the committee will evaluate Semax (free base and acetate) for cerebral ischaemia, migraine, and trigeminal neuralgia, and Emideltide/DSIP (free base and acetate) for opioid withdrawal, chronic insomnia, and narcolepsy.

Selank occupies a different regulatory position. It was removed from Category 2 in September 2024 when the nominator withdrew and has been referred to the PCAC process, but no specific review date has been announced. Dihexa acetate is scheduled for PCAC review before February 2027. Cerebrolysin, as a proprietary mixture rather than a single bulk drug substance, follows a different regulatory pathway entirely.

A critical question for the PCAC: how will the committee evaluate compounds whose clinical evidence exists primarily in Russian-language literature? The evidentiary standard for 503A Bulks List inclusion requires demonstrated safety and clinical utility, but the FDA’s traditional framework relies on English-language publications meeting specific trial design standards. The outcome may set a precedent for how non-Western pharmaceutical data is weighed in US compounding decisions. For how peptide legality works across jurisdictions, see our guides for the US, the UK and Australia.

The bottom line: the July 2026 PCAC hearing will evaluate Semax and DSIP for compounding eligibility, while Selank awaits scheduling and Dihexa is targeted for early 2027 – making the next 12 months the most consequential regulatory period for nootropic peptides in US history.

What is the most studied nootropic peptide?

Semax has the deepest molecular characterisation, with genome-wide transcriptome studies, detailed BDNF data, and over 40 years of research history. Selank has more human clinical trial data, with over 250 patients enrolled across multiple active-controlled trials. Cerebrolysin has the broadest international clinical programme, with studies conducted across multiple countries. The answer depends on what kind of evidence matters most to you.

Are nootropic peptides legal?

Legality varies by compound and jurisdiction. In Russia, both Semax and Selank are approved prescription medications. In the US, none are FDA-approved; Semax and DSIP are scheduled for PCAC review in July 2026 that could open a legal compounding pathway under Section 503A. In the UK and Australia, they are neither approved nor specifically controlled. See our individual country guides for detailed legal analysis.

Can Semax and Selank be used together?

The Semax-Selank combination is one of the most established peptide pairings in both Russian clinical practice and the research community. They act through complementary mechanisms – Semax provides cognitive stimulation via BDNF and dopamine, Selank provides calming anxiolysis via GABA and enkephalin stabilisation. No controlled combination study has been published, but the pairing has extensive observational use and is considered standard practice by many Russian clinicians.

Why is all the evidence from Russia?

Semax and Selank were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Russian regulatory system approved them based on Russian clinical data conducted under Russian evidentiary standards. Western researchers had no commercial incentive to replicate these studies because the compounds had no Western regulatory pathway. The PCAC process may change this dynamic by creating a US framework for evaluating non-Western pharmaceutical evidence.

What happens at the PCAC hearing?

The PCAC is an advisory committee that evaluates whether bulk drug substances should be added to the Section 503A list, which permits their use in compounding by licensed pharmacies with a valid prescription. The committee hears presentations from nominators, reviews FDA staff analyses, takes public comment, and makes recommendations. Those recommendations are advisory – the FDA makes the final decision through a subsequent rulemaking process. A positive recommendation does not guarantee inclusion, but PCAC recommendations carry significant weight.